Sparsentan receives Orphan Drug Designation for primary IgA nephropathy in Japan ...Middle East

TOKYO, Dec. 2, 2024 /PRNewswire/ -- Renalys Pharma, Inc., a late-stage clinical biopharmaceutical company announces that sparsentan, in-licensed from Travere Therapeutics, Inc. ("Travere") and currently in phase III clinical trials in Japan, has received Orphan Drug Designation from the...

Read More Details
Finally We wish PressBee provided you with enough information of ( Sparsentan receives Orphan Drug Designation for primary IgA nephropathy in Japan )

Also on site :

• Iconic Sitcom Actress, 67, Stuns With Ageless Appearance 20 Years After Show Ended
• Numbrix 9 - June 19
• Putin rejects question about any potential attempt to kill Iran’s Khamenei